UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042257
Receipt number R000048250
Scientific Title Validation study about halitosis-reducing effects by long-term usage of zinc chloride-containing toothpaste and copper gluconate-containing mouth-rinse solution
Date of disclosure of the study information 2021/09/21
Last modified on 2021/07/27 10:31:04

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Validation study about halitosis-reducing effects by long-term usage of zinc chloride-containing toothpaste and copper gluconate-containing mouth-rinse solution

Acronym

Validation study about halitosis-reducing effects by long-term usage of zinc chloride-containing toothpaste and copper gluconate-containing mouth-rinse solution

Scientific Title

Validation study about halitosis-reducing effects by long-term usage of zinc chloride-containing toothpaste and copper gluconate-containing mouth-rinse solution

Scientific Title:Acronym

Validation study about halitosis-reducing effects by long-term usage of zinc chloride-containing toothpaste and copper gluconate-containing mouth-rinse solution

Region

Japan


Condition

Condition

Healthy male adults

Classification by specialty

Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To verify halitosis-reducing effects by test-product usage for 4 weeks

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Concentrations of volatile sulfur compounds, such as H2S, Me3SH and Me2S

Key secondary outcomes

1. Gingivitis index
2. Swelling
3. Reddening
4. Overall effectiveness
5. Tongue coating


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

No treatment

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Other

Interventions/Control_1

Continuous application of the toothpaste to the subjects, three times a day (after every meal) for 4 weeks.

Interventions/Control_2

Continuous application of the mouth-wash solution to the subjects, three times a day (after every meal) for 4 weeks.

Interventions/Control_3

Continuous application of both the toothpaste and the solution to the subjects, three times a day (after every meal) for 4 weeks.

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

50 years-old >

Gender

Male

Key inclusion criteria

(1) Healthy male subjects ranging in age from 20 to 49 years old.
(2) Subjects equipped with not less than 20 teeth, and without some kind of periodontal disease.
(3) Subjects having mild-to-moderate gingivitis.
(4) Subjects with bad breath at steady state.
(5) Subjects having meals three times a day, and toothbrushing after each meal.
(6) Subjects having not less than four teeth among measurable six teeth (FDI: 16, 21, 24, 36, 41, 44), or their alternatives (FDI: 17, 15, 11, 22, 25, 37, 35, 31, 42, 45).
(7) Subjects who gave informed consent to take part in this trial after being provided with an explanation of the protocol detail.

Key exclusion criteria

(1) At the screening test, subjects who were determined as a patient having some dental caries (over C3 level) and/or severe periodontal disease.
(2) Subjects with medical treatment for diabetic, chronic kidney, digestive, lung or cancer diseases.
(3) Subjects having need of some kind of scaling with oral surgery treatment and/or anesthesia.
(4) Subjects with some kind of allergy.
(5) Subjects equipped with removable denture.
(6) Subjects with smoking habit.
(7) Subjects who are now under the other clinical trials with some kind of medicine/food, or going to take part in those trials.
(8) Subjects who have took in some kind of antibiotic and/or antibacterial agent, regularly or within the last month to the screening test.
(9) All through this trial, subjects who have any difficulty in refraining from using some kind of mouth-rinse solution and/or interdental brush.
(10) Others who have been determined as ineligible for participation, judging from the principal/sub investigator's opinions.

Target sample size

30


Research contact person

Name of lead principal investigator

1st name Tomohiko
Middle name
Last name Yamaguchi

Organization

DAIICHI SANKYO HEALTHCARE CO.,LTD

Division name

Chief Director

Zip code

140-8710

Address

3-14-10 Nihonbashi, Chuo-ku, Tokyo 140-8710, Japan

TEL

03-5225-6330

Email

yamaguchi.tomohiko.m6@daiichisankyo-hc.co.jp


Public contact

Name of contact person

1st name Eiji
Middle name
Last name Yoshikawa

Organization

KSO Corporation

Division name

Sales department

Zip code

105-0023

Address

7F Shibaura-Omodaka Building, 1-9-7 Shibaura, Minato-ku, Tokyo 105-0023, Japan

TEL

03-3452-7733

Homepage URL


Email

yoshikawa@kso.co.jp


Sponsor or person

Institute

KSO Corporation

Institute

Department

Personal name



Funding Source

Organization

DAIICHI SANKYO HEALTHCARE CO.,LTD

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Committee of Nihonbashi Cardiology Clinic

Address

Kyodo Building, 13-4-201 Nihonbashi-Kodenma-Cho, Chuo-ku, Tokyo 103-0001, Japan

Tel

03-5641-4133

Email

niho-jimucho@well-sleep.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 09 Month 21 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2020 Year 09 Month 04 Day

Date of IRB

2020 Year 08 Month 06 Day

Anticipated trial start date

2020 Year 09 Month 21 Day

Last follow-up date

2020 Year 11 Month 29 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2020 Year 10 Month 27 Day

Last modified on

2021 Year 07 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048250


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name